Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744537 | 0.78 | MPO (0.38) | DAOKDM4EGAAGFERPCSK9 | |
| SCHEMBL3747948 | 0.77 | ADRA2A (0.53) | KDM4EALDH1A1GAAGFERTAAR1 | |
| SCHEMBL14066591 | 0.74 | SLC22A4 (0.42) | DAOKDM4EALDH1A1GAAGFER | |
| SCHEMBL2744943 | 0.71 | ALDH1A1 (0.46) | DAOKDM4EALDH1A1GAAGFER | |
| SCHEMBL20117714 | 0.71 | DAO (0.49) | DAOKDM4EALDH1A1F2TAAR1 | |
| SCHEMBL3301625 | 0.70 | TAAR1 (0.59) | DAOKDM4EALDH1A1TAAR1AR | |
| SCHEMBL2744493 | 0.69 | PTGDR2 (0.37) | DAOKDM4EGAAGFERIDO1 | |
| SCHEMBL3747110 | 0.69 | DAO (0.41) | DAOKDM4EALDH1A1 | |
| SCHEMBL3747917 | 0.68 | MTNR1A (0.41) | DAOKDM4E | |
| SCHEMBL3746960 | 0.68 | KDM4E (0.38) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196911-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196911-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8178571-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178571-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178571-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1797044-A2 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | Allergan, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006036512-A2 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069142-A1 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069142-A1 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ADRB2, ADRB1, ADRA2C | DAO 1771/4885KDM4E 3761/4885ALDH1A1 417/4885 |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ADRB2, ADRB1, ADRA2C | DAO 1771/4885KDM4E 3761/4885ALDH1A1 417/4885 |
| US-20120196911-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ADRB2, ADRB1, ADRA2C | DAO 1771/4885KDM4E 3761/4885ALDH1A1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.